Coronavirus

The self-amplifying mRNA vaccine, ARCT-154, had an extended response compared to the BNT162b2 vaccine and was approved in Japan back in November.

CDC endorses the role of antiviral drugs in combating COVID-19.

This news comes after the World Health Organization (WHO) recently granted the vaccine an emergency use listing (EUL), and continues to become available to more countries.

A small study offers some more information as to potential biomarkers for the ailment and may provide a better understanding of its path to potential treatments.

Early administration of simnotrelvir plus ritonavir shortened the time to sustained resolution of COVID-19 symptoms.

Investigators uncover a convergent evolution of enhanced innate immune antagonist expression associated.

Here are some insights into the comparative analysis of COVID and non-COVID pneumonia.

Myopathy, with metabolic disturbances and amyloid deposits, is discovered in persons with Long COVID who experience post-exertional malaise.

Results of a study by Yan Xie and colleagues highlight the severe impact of COVID-19, with higher death rates, increased risks of long-term complications, and greater infectivity compared to seasonal influenza.

A study used real-world CDC data to calculate the number of people who needed to be vaccinated to prevent both medical events in the greater community.

In 43 of 154 school weeks, air samples were positive for influenza A virus (IAV) while SARS-CoV-2 was positive in air samples in 101 of 154 school weeks.

Biopharmaceutical company, Invivyd, made the request to the FDA for its investigational antibody, VYD222.

In a new survey, respondents said both vaccines were efficacious, but a higher share said influenza vaccines were very safe compared to COVID-19 vaccines. This demonstrates a public health concern considering the higher incidence rates and hospitalizations of COVID-19 over the flu, and the possibility of low vaccine intakes.

United Kingdom-based Virax Biolabs is a biotech company that is focused on the detection and diagnosis of viral diseases, with a particular interest in the enigmatic, Long COVID.

The ARCT-154 vaccine from CSL and Arcturus Therapeutics was approved in adults.

A comprehensive cohort study explored the impact of inactivated COVID-19 vaccines administered within 3 months before conception, revealing reassuring findings that neonatal outcomes, including preterm birth and NICU admission, remain unaffected.

This bipartisan initiative highlights the need for a comprehensive approach to combat antimicrobial resistance (AMR), incorporating both antibiotic drug development and increased funding for stewardship programs.

The FDA and CDC announced the availability of additional doses of nirsevimab-alip for infants at high-risk of infection.

Shionogi’s therapy, ensitrelvir, was found to reduce and prevent these issues.

ACON Laboratories’ Flowflex COVID-19 Antigen Home Test completed the premarket review pathway and is the first test indicated for use in children under 18.

The federal agency was made aware some health care providers had administered the full single dose vial of the vaccine, which contains “notably more” volume than the 0.25 mL volume indicated for children aged 6 months to 11 years.

This discussion revolves around diagnostics for viruses and best practices and challenges.

Two RSV vaccines for seniors were FDA approved this year and here is an overview of the vaccines and the study data.

Veterans Affairs (VA) study finds some reduction in post-COVID thromboembolic events with early use of nirmatrelvir-ritonavir but no protection against 30 other conditions.

Imprecise language can fuel infodemics and misinformation and damage public trust.

A new study that went beyond the current standard of testing for the respiratory virus resulted in greater incidence rates and a truer accounting of case loads.

The company dosed its first study participant with its investigational vaccine, mRNA-1083. And this follows recent data reported from their phase 1/2 trial where the vaccine showed strong immunogenicity against influenza and COVID-19, with an acceptable reactogenicity and safety profile.

The federal agency sent out a health advisory to change the prescribing recommendations for the newer preventative respiratory syncytial virus (RSV) monoclonal antibody.

If approved, it would become the first nasal flu vaccine to be self-administered.

Association with Epstein-Barr virus reactivation sets the need for an antiviral clinical trial with cardiopulmonary exercise testing as an endpoint.